BPC-157 Dosing Guide

BPC-157 Dosing Calculator

BPC-157 dosing is often based on body weight for optimal results. Use this calculator to determine your personalized dose based on research protocols:

Research Dosing Ranges

BPC-157 dosing in humans is entirely based on extrapolation from animal studies and anecdotal reports from self-experimenters. There are no FDA-approved dosing guidelines, no phase 3 clinical trials establishing optimal doses, and no long-term safety data. The doses commonly discussed in online communities and research forums represent educated guesses rather than scientifically validated protocols.

Animal Study Doses (For Reference)

In animal research, BPC-157 has been studied at doses ranging from 10 mcg/kg to 10 mg/kg body weight, depending on the condition being studied and the route of administration. Most studies showing therapeutic effects used doses in the range of 10-20 mcg/kg. For a 70 kg (154 lb) human, this would translate to approximately 700-1,400 mcg (0.7-1.4 mg) per day.

Commonly Reported Human Doses

Based on anecdotal reports and online discussions, individuals experimenting with BPC-157 typically use:

• Low dose: 200-300 mcg per day (100-150 mcg twice daily)
• Moderate dose: 400-600 mcg per day (200-300 mcg twice daily)
• High dose: 800-1,000 mcg per day (400-500 mcg twice daily)

These doses are significantly lower than those used in animal studies when adjusted for body weight, reflecting a conservative approach given the lack of human safety data. However, it's important to emphasize that even these "commonly used" doses have no scientific validation for safety or efficacy in humans.

Dosing Frequency

Twice Daily Administration

BPC-157 has a relatively short half-life estimated at 4-6 hours based on its peptide structure and animal pharmacokinetic data. Most users report administering BPC-157 twice daily (morning and evening) to maintain more consistent blood levels. This approach mirrors the dosing schedules used in many animal studies.

Once Daily Administration

Some individuals use BPC-157 once daily, typically in the morning. This approach may be sufficient for systemic effects, though it results in greater fluctuation in blood levels throughout the day. Once-daily dosing is more convenient but may be less optimal for conditions requiring sustained peptide exposure.

Timing Considerations

There is no established optimal timing for BPC-157 administration. Some users prefer:

• Morning and evening: Provides most consistent blood levels
• Pre-workout and post-workout: Theoretical benefit for injury recovery
• Before meals: May enhance gastric protection effects
• Before bed: Aligns with natural tissue repair processes during sleep

None of these timing strategies have been validated in human studies.

Routes of Administration

Subcutaneous Injection

Subcutaneous (SubQ) injection is the most common route of administration for BPC-157. This method provides reliable absorption and bioavailability, though exact bioavailability in humans is unknown. SubQ injection is typically performed in the abdomen, thigh, or upper arm using insulin syringes.

SubQ Injection Technique:

1. Wash hands thoroughly with soap and water
2. Clean injection site with alcohol swab and let dry
3. Pinch skin to create a fold
4. Insert needle at 45-90 degree angle
5. Inject slowly over 5-10 seconds
6. Withdraw needle and apply gentle pressure
7. Rotate injection sites to prevent tissue damage

Intramuscular Injection

Intramuscular (IM) injection is less common but may be preferred for localized injuries. Some users inject BPC-157 directly into or near injured muscles, tendons, or joints, theorizing that local administration provides higher concentrations at the injury site. However, there is no human data supporting superior efficacy of local versus systemic administration.

Oral Administration

BPC-157 is unusual among peptides in that it appears to have some oral bioavailability. Animal studies have shown therapeutic effects with oral administration, though the exact bioavailability is unknown and likely much lower than injection. Oral BPC-157 is typically taken as a capsule or dissolved in water.

Oral Dosing Considerations:

• May require higher doses than injection (2-3x) due to lower bioavailability
• Commonly reported oral doses: 500-1,500 mcg per day
• May be particularly effective for gastrointestinal conditions
• More convenient but potentially less cost-effective
• Stability in stomach acid is uncertain

Nasal Spray

Some users report using BPC-157 as a nasal spray, particularly for neurological or cognitive applications. The nasal route can bypass the blood-brain barrier via olfactory pathways, potentially delivering peptides directly to the brain. However, there is no research validating this approach for BPC-157, and appropriate dosing is entirely speculative.

Reconstitution Instructions

What You'll Need

• BPC-157 lyophilized powder (typically 5 mg vial)
• Bacteriostatic water (preferred) or sterile water
• Alcohol swabs
• Insulin syringes (0.3 mL or 0.5 mL with 29-31 gauge needles)
• Sterile vial for mixing (if not mixing in original vial)

Step-by-Step Reconstitution

1. Calculate volume needed: Determine how much bacteriostatic water to add based on desired concentration. For example, adding 2 mL to a 5 mg vial creates a concentration of 2.5 mg/mL (2,500 mcg/mL).
2. Clean vial tops: Wipe the tops of both the BPC-157 vial and bacteriostatic water vial with alcohol swabs.
3. Draw bacteriostatic water: Using a syringe, draw the calculated amount of bacteriostatic water.
4. Add water to peptide: Slowly inject the water into the BPC-157 vial, aiming for the side of the vial rather than directly onto the powder.
5. Gentle mixing: Gently swirl the vial (do not shake vigorously) until the powder is completely dissolved. This may take 1-2 minutes.
6. Inspect solution: The solution should be clear and colorless. If cloudy or contains particles, do not use.
7. Label vial: Mark the vial with the concentration, date of reconstitution, and expiration date.

Concentration Examples

Common reconstitution volumes for a 5 mg vial:

• 2 mL bacteriostatic water: 2,500 mcg/mL (0.1 mL = 250 mcg)
• 2.5 mL bacteriostatic water: 2,000 mcg/mL (0.1 mL = 200 mcg)
• 5 mL bacteriostatic water: 1,000 mcg/mL (0.1 mL = 100 mcg)

Dosing Calculations

To calculate injection volume for desired dose:

Volume (mL) = Desired dose (mcg) ÷ Concentration (mcg/mL)

Example: For 250 mcg dose with 2,500 mcg/mL concentration:
Volume = 250 ÷ 2,500 = 0.1 mL (10 units on insulin syringe)

Storage Requirements

Lyophilized Powder

Unopened BPC-157 powder should be stored:

• Short-term (up to 6 months): Refrigerator at 2-8°C (36-46°F)
• Long-term (up to 2 years): Freezer at -20°C (-4°F) or colder
• Protect from light by keeping in original packaging
• Keep away from moisture

Reconstituted Solution

Once reconstituted with bacteriostatic water:

• Store in refrigerator at 2-8°C (36-46°F)
• Use within 28 days (bacteriostatic water preservative effective for 28 days)
• Protect from light by wrapping vial in aluminum foil or storing in dark container
• Do not freeze reconstituted solution
• Discard if solution becomes cloudy or discolored

Sterile Water vs. Bacteriostatic Water

Bacteriostatic water contains 0.9% benzyl alcohol as a preservative, allowing multiple withdrawals over 28 days. Sterile water has no preservative and should be used within 24 hours of reconstitution. For BPC-157 used twice daily, bacteriostatic water is strongly preferred for convenience and reduced contamination risk.

Cycle Length and Protocols

Acute Injury Protocol

For acute injuries (muscle strains, tendon injuries, ligament sprains), anecdotal reports suggest:

• Duration: 4-6 weeks
• Dose: 400-600 mcg per day (200-300 mcg twice daily)
• Route: Subcutaneous injection, potentially near injury site
• Assessment: Evaluate improvement at 2-week intervals
• Extension: May continue up to 8-12 weeks if showing continued improvement

Chronic Condition Protocol

For chronic conditions (inflammatory bowel disease, chronic tendinopathy, chronic pain), some users report longer cycles:

• Duration: 8-12 weeks initial trial
• Dose: 300-500 mcg per day
• Route: Subcutaneous or oral
• Maintenance: Some users continue long-term at reduced doses (200-300 mcg per day)
• Cycling: Others cycle 8-12 weeks on, 4-8 weeks off

Gastrointestinal Protocol

For gastrointestinal conditions, oral administration may be preferred:

• Duration: 4-8 weeks
• Dose: 500-1,000 mcg per day orally
• Timing: Before meals or on empty stomach
• Assessment: Monitor symptoms weekly

When to Discontinue

Consider stopping BPC-157 if:

• No improvement after 4-6 weeks of consistent use
• Adverse effects develop
• Condition has fully resolved
• Diminishing returns observed (plateau in improvement)

Overdose Information

Can BPC-157 Overdose Be Fatal?

There are no reported cases of fatal BPC-157 overdose in animal studies or human anecdotal reports. In animal toxicity studies, BPC-157 has shown remarkably low toxicity even at doses far exceeding therapeutic ranges. However, the lack of human clinical trials means that the true overdose potential and serious adverse effects remain unknown.

Potential Overdose Effects

Based on limited data, potential effects of excessive BPC-157 doses might include:

• Injection site reactions: Pain, redness, swelling at injection site
• Headache: Reported by some users at higher doses
• Fatigue or drowsiness: Anecdotal reports of sedation
• Nausea: Particularly with oral administration
• Blood pressure changes: BPC-157 affects nitric oxide pathways
• Dizziness: Possibly related to blood pressure effects

Theoretical Concerns

Given BPC-157's mechanisms of action, theoretical overdose concerns include:

• Excessive angiogenesis: Could theoretically promote tumor growth or abnormal blood vessel formation
• Immune system effects: Unknown impact of chronic high-dose exposure
• Hormonal disruption: Effects on growth hormone and other hormonal pathways
• Coagulation changes: Potential effects on blood clotting

Overdose Management

If accidental overdose occurs:

1. Discontinue BPC-157 immediately
2. Monitor for adverse symptoms
3. Seek medical attention if severe symptoms develop
4. Inform healthcare provider about BPC-157 use
5. Do not resume use until symptoms resolve
6. If resuming, start at lower dose

Safety Monitoring

Baseline Assessment

Before starting BPC-157, consider obtaining:

• Complete blood count (CBC)
• Comprehensive metabolic panel
• Liver function tests
• Kidney function tests
• Blood pressure measurement
• Documentation of current symptoms/condition

Ongoing Monitoring

During BPC-157 use, monitor for:

• Changes in symptoms or condition being treated
• New symptoms or side effects
• Injection site reactions
• Changes in energy, mood, or sleep
• Blood pressure changes
• Any unusual symptoms

When to Seek Medical Attention

Stop BPC-157 and consult a healthcare provider if you experience:

• Severe injection site reactions (abscess, severe pain, spreading redness)
• Allergic reactions (rash, difficulty breathing, swelling)
• Severe headaches or vision changes
• Chest pain or irregular heartbeat
• Severe abdominal pain
• Signs of blood clots (leg pain, swelling, warmth)
• Any other concerning symptoms

Drug Interactions

Known and Theoretical Interactions

Due to lack of human studies, drug interactions with BPC-157 are largely theoretical. Potential interactions include:

Blood Thinners (Warfarin, Heparin, DOACs)

BPC-157 affects angiogenesis and vascular healing, which could theoretically interact with anticoagulants. Use caution and monitor for bleeding or clotting changes.

NSAIDs (Ibuprofen, Naproxen)

BPC-157 is being studied for its ability to protect against NSAID-induced gastric damage. While this suggests potential benefit, the interaction is not well understood. Some users report taking both without issues.

Growth Hormone and IGF-1

BPC-157 may influence growth hormone pathways. Combining with exogenous growth hormone or IGF-1 could have additive or synergistic effects, though this is speculative.

Other Peptides

Many users combine BPC-157 with other peptides (TB-500, GHK-Cu, etc.). While anecdotal reports suggest this is generally well-tolerated, there is no research on peptide combinations.

Substances to Avoid

Consider avoiding or using caution with:

• Alcohol (may impair healing and increase gastric irritation)
• Tobacco (counteracts healing effects)
• Corticosteroids (may interfere with healing mechanisms)

Cost Considerations

Pricing

BPC-157 pricing varies widely by source and purity:

• Research chemical suppliers: $30-80 per 5 mg vial
• Peptide clinics: $100-300 per 5 mg vial
• Compounding pharmacies: $150-400 per 5 mg vial

Monthly Cost Estimates

Based on common dosing protocols:

• Low dose (300 mcg/day): 1.5 vials/month = $45-120/month
• Moderate dose (500 mcg/day): 2.5 vials/month = $75-200/month
• High dose (800 mcg/day): 4 vials/month = $120-320/month

Quality Considerations

BPC-157 quality varies significantly between suppliers. Higher-priced products may offer:

• Third-party purity testing (HPLC, mass spectrometry)
• Certificates of analysis
• Pharmaceutical-grade manufacturing
• Sterility testing
• Proper storage and handling

Cheaper products may have lower purity, contamination, or incorrect dosing. Given the lack of FDA oversight, quality assurance is a significant concern.